Take Control of Your CML Journey with Precision Monitoring
Living with Chronic Myeloid Leukaemia can feel overwhelming, but having clear, reliable information about your treatment response brings peace of mind and confidence. Our BCR-ABL Major Quantitative Test is specifically designed to give you and your healthcare team the precise data needed to ensure your therapy is working effectively.
Understanding Your BCR-ABL Test
The BCR-ABL Major Quantitative Test measures the amount of BCR-ABL fusion gene in your blood or bone marrow. This specific genetic abnormality is what drives Chronic Myeloid Leukaemia progression. By tracking these levels over time, your doctor can determine how well your treatment is working and make adjustments if needed.
Using advanced Real-Time PCR technology, we provide highly accurate measurements that help monitor your response to targeted therapies. This isn’t just a test – it’s your roadmap to effective CML management.
Who Should Consider This Test?
This test is essential for anyone diagnosed with Chronic Myeloid Leukaemia who is undergoing treatment. If you’re experiencing:
- Concerns about treatment effectiveness
- Need for regular monitoring of your CML status
- Recent changes in medication or dosage
- Planning for treatment adjustments with your oncologist
- Following up on previous BCR-ABL test results
Regular monitoring helps catch any changes early, allowing for timely treatment adjustments that can significantly improve outcomes.
Why This Test Matters for Your Health Journey
Early detection of treatment resistance can be life-changing. The BCR-ABL Major Quantitative Test provides:
- Peace of Mind: Know your treatment is working effectively
- Early Intervention: Detect resistance before symptoms appear
- Personalised Care: Help your doctor tailor your treatment plan
- Improved Outcomes: Stay ahead of your CML progression
- Reduced Anxiety: Replace uncertainty with clear data
Understanding Your Results with Confidence
Your results will show the percentage of BCR-ABL fusion gene compared to a control gene. Lower numbers indicate better treatment response. Our team provides clear explanations, and we recommend discussing results with your oncologist to understand what they mean for your specific situation.
Remember: Regular monitoring helps establish trends over time, which is more valuable than any single result.
Transparent Pricing – Your Health Investment
| Test | Regular Price | Special Price | Savings |
|---|---|---|---|
| BCR-ABL Major Quantitative Test | ZAR 4,000 | ZAR 3,400 | ZAR 600 |
This investment in precise monitoring can help prevent costly complications and hospitalisations down the line.
Why Trust Oracle Genomics?
We understand that cancer monitoring requires absolute precision and compassion. Our commitment to you includes:
- Nationwide Coverage: Accessible testing across South Africa including Johannesburg, Cape Town, Durban, and Pretoria
- Rapid Results: Email results in 36 hours or phone consultation within 24 hours
- Medical Expertise: Specialised oncology testing with physician oversight
- Patient-Centred Care: We treat you with the dignity and respect you deserve
- Advanced Technology: Real-Time PCR for unmatched accuracy
Simple Preparation for Your Test
Getting tested is straightforward. You’ll need to:
- Sign a consent document at our facility
- Bring any relevant clinical history for your BCR-ABL test
- Provide a sample of whole blood, culture cells, or bone marrow aspiration
Our caring staff will guide you through every step with compassion and professionalism.
Take the Next Step in Your CML Management
Don’t leave your treatment response to chance. Early monitoring can make all the difference in your CML journey. Book your BCR-ABL Major Quantitative Test today and gain the clarity you need to move forward with confidence.
Call us now to schedule your test or book online for immediate confirmation. Our team is ready to support you with the compassionate, professional care you deserve.
Your health journey matters – let us help you navigate it with precision and care.
